586 related articles for article (PubMed ID: 15235686)
1. Anticoagulation period in idiopathic venous thromboembolism. How long is enough?
Farraj RS
Saudi Med J; 2004 Jul; 25(7):848-51. PubMed ID: 15235686
[TBL] [Abstract][Full Text] [Related]
2. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism.
Kearon C; Gent M; Hirsh J; Weitz J; Kovacs MJ; Anderson DR; Turpie AG; Green D; Ginsberg JS; Wells P; MacKinnon B; Julian JA
N Engl J Med; 1999 Mar; 340(12):901-7. PubMed ID: 10089183
[TBL] [Abstract][Full Text] [Related]
3. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism.
Ridker PM; Goldhaber SZ; Danielson E; Rosenberg Y; Eby CS; Deitcher SR; Cushman M; Moll S; Kessler CM; Elliott CG; Paulson R; Wong T; Bauer KA; Schwartz BA; Miletich JP; Bounameaux H; Glynn RJ;
N Engl J Med; 2003 Apr; 348(15):1425-34. PubMed ID: 12601075
[TBL] [Abstract][Full Text] [Related]
4. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators.
Agnelli G; Prandoni P; Santamaria MG; Bagatella P; Iorio A; Bazzan M; Moia M; Guazzaloca G; Bertoldi A; Tomasi C; Scannapieco G; Ageno W;
N Engl J Med; 2001 Jul; 345(3):165-9. PubMed ID: 11463010
[TBL] [Abstract][Full Text] [Related]
5. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group.
Schulman S; Granqvist S; Holmström M; Carlsson A; Lindmarker P; Nicol P; Eklund SG; Nordlander S; Lärfars G; Leijd B; Linder O; Loogna E
N Engl J Med; 1997 Feb; 336(6):393-8. PubMed ID: 9010144
[TBL] [Abstract][Full Text] [Related]
6. Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. Duration of Anticoagulation Trial.
Schulman S; Lindmarker P
N Engl J Med; 2000 Jun; 342(26):1953-8. PubMed ID: 10874063
[TBL] [Abstract][Full Text] [Related]
7. The outpatient bleeding risk index: validation of a tool for predicting bleeding rates in patients treated for deep venous thrombosis and pulmonary embolism.
Wells PS; Forgie MA; Simms M; Greene A; Touchie D; Lewis G; Anderson J; Rodger MA
Arch Intern Med; 2003 Apr; 163(8):917-20. PubMed ID: 12719200
[TBL] [Abstract][Full Text] [Related]
8. Extended prophylaxis of venous thromboembolism with idraparinux.
; Buller HR; Cohen AT; Davidson B; Decousus H; Gallus AS; Gent M; Pillion G; Piovella F; Prins MH; Raskob GE
N Engl J Med; 2007 Sep; 357(11):1105-12. PubMed ID: 17855671
[TBL] [Abstract][Full Text] [Related]
9. Oral anticoagulation strategies after a first idiopathic venous thromboembolic event.
Aujesky D; Smith KJ; Roberts MS
Am J Med; 2005 Jun; 118(6):625-35. PubMed ID: 15922694
[TBL] [Abstract][Full Text] [Related]
10. Risk of venous thromboembolism recurrence: high negative predictive value of D-dimer performed after oral anticoagulation is stopped.
Palareti G; Legnani C; Cosmi B; Guazzaloca G; Pancani C; Coccheri S
Thromb Haemost; 2002 Jan; 87(1):7-12. PubMed ID: 11848459
[TBL] [Abstract][Full Text] [Related]
11. 6 versus 30 months anticoagulation for recurrent venous thrombosis in patients with high factor VIII.
Eischer L; Gartner V; Schulman S; Kyrle PA; Eichinger S;
Ann Hematol; 2009 May; 88(5):485-90. PubMed ID: 18931845
[TBL] [Abstract][Full Text] [Related]
12. Oral anticoagulant therapy in venous thromboembolism.
Cosmi B; Palareti G
Semin Vasc Med; 2003 Aug; 3(3):303-14. PubMed ID: 15199464
[TBL] [Abstract][Full Text] [Related]
13. [Complications and risks associated with an anticoagulation therapy combining low molecular weight heparin and Warfarin after total replacement of large joints--our experience].
Míka P; Behounek J; Skoták M; Nevsímal L
Acta Chir Orthop Traumatol Cech; 2004; 71(4):237-44. PubMed ID: 15456102
[TBL] [Abstract][Full Text] [Related]
14. Extended anticoagulation for a first episode of idiopathic venous thromboembolism.
Sparano N; English R
J Fam Pract; 1999 Aug; 48(8):579-80. PubMed ID: 10496632
[No Abstract] [Full Text] [Related]
15. Duration of anticoagulation after first episode of unprovoked venous thromboembolism.
Abdel-Razeq HN; Radwi GR
Saudi Med J; 2004 Nov; 25(11):1776; author reply 1776-7. PubMed ID: 15573235
[No Abstract] [Full Text] [Related]
16. Six Months vs Extended Oral Anticoagulation After a First Episode of Pulmonary Embolism: The PADIS-PE Randomized Clinical Trial.
Couturaud F; Sanchez O; Pernod G; Mismetti P; Jego P; Duhamel E; Provost K; dit Sollier CB; Presles E; Castellant P; Parent F; Salaun PY; Bressollette L; Nonent M; Lorillon P; Girard P; Lacut K; Guégan M; Bosson JL; Laporte S; Leroyer C; Décousus H; Meyer G; Mottier D;
JAMA; 2015 Jul; 314(1):31-40. PubMed ID: 26151264
[TBL] [Abstract][Full Text] [Related]
17. Outpatient management of anticoagulation therapy.
du Breuil AL; Umland EM
Am Fam Physician; 2007 Apr; 75(7):1031-42. PubMed ID: 17427618
[TBL] [Abstract][Full Text] [Related]
18. Plasma coagulation markers in patients with solid tumors and venous thromboembolic disease receiving oral anticoagulation therapy.
Sallah S; Husain A; Sigounas V; Wan J; Turturro F; Sigounas G; Nguyen NP
Clin Cancer Res; 2004 Nov; 10(21):7238-43. PubMed ID: 15534097
[TBL] [Abstract][Full Text] [Related]
19. [Thrombin-activated inhibitor of fibrinolysis and efficacy and safety of long-term warfarin treatment in patients with venous thromboembolic complications].
Vorob'eva NM; Panchenko EP; Dobrovol'skiĭ AB; Titaeva EV; Ermolina OV; Balakhonova TV; Khasanova ZB; Postnov AIu; Kirienko AI
Ter Arkh; 2011; 83(12):43-8. PubMed ID: 22416444
[TBL] [Abstract][Full Text] [Related]
20. Venous thromboembolism: risk factors for recurrence.
Zhu T; Martinez I; Emmerich J
Arterioscler Thromb Vasc Biol; 2009 Mar; 29(3):298-310. PubMed ID: 19228602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
